Clinical trials: Cholangiocarcinoma Cancer
Cholangiocarcinoma
Carlizumab Plus Sovantinib in Second-line Treatment of Advanced or Metastatic Cholangiocarcinoma
The incidence of cholangiocarcinoma is high, the radical resection rate is low, the postoperative recurrence is easy, the prognosis is poor.Gemcitabine combined with cisplatin (GC) is the standard first-line treatment for…
- Trial name
- NCT05697237
- Testing
- Carrelizumab, Solfantinib
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Cancer
Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen
RATIONALE: Antiemetic drugs may help to reduce or prevent vomiting in patients treated with radiation therapy. It is not yet known if ondansetron is more effective with or without dexamethasone in preventing vomiting caused by…
- Trial name
- NCT00016380
- Testing
- dexamethasone, ondansetron, quality-of-life assessment
- Where
- 14 sites in Canada
- Volunteers
- 211 people
- Sponsor
- NCIC Clinical Trials Group
Liver Cancer
Precision Medicine for Combined Hepatocellular-Cholangiocarcinoma
Our project is a large-scale characterisation of cHCC-CCA will allow us to determine which subsets harbor actionable gene alterations.
- Trial name
- PREMED-CHC (NCT06146127)
- Testing
- phenotyping
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Inserm U955
Intrahepatic Cholangiocarcinoma
TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma
The objective of this study is to evaluate the efficacy and safety of TACE combined with Tislelizumab in patients with advanced intrahepatic cholangiocarcinoma after progression on first-line systemic therapy.
- Trial name
- NCT04954781
- Testing
- Tislelizumab, TACE
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Cancer
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
RATIONALE: Hepatic arterial infusion uses a catheter to deliver anticancer substances directly into the liver. Drugs used in chemotherapy, such as melphalan, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00096083
- Testing
- isolated perfusion, melphalan
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Delcath Systems Inc.
Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
This is a phase 1/1b open label, multicenter dose escalation and dose expansion study to investigate the safety, tolerability and anti-tumor activity of TPST-1120, a small molecule selective antagonist of PPARα (peroxisome…
- Conditions
- Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT03829436
- Testing
- Part 1 TPST-1120, Part 2 TPST-1120 + nivolumab, Part 3 TPST-1120
- Where
- 11 sites in United States
- Volunteers
- 38 people
- Sponsor
- Tempest Therapeutics
Biliary Tract Cancer
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
The purpose of this study is to measure the efficacy and safety of rilvegostomig with gemcitabine plus cisplatin vs. durvalumab with gemcitabine plus cisplatin as first line treatment for patients with advanced BTC.
- Trial name
- AB02 (NCT07221253)
- Testing
- Rilvegostomig, Durvalumab, Gemcitabine/Cisplatin
- Where
- 183 sites in United States, Australia and 17 more
- Volunteers
- 1,100 people
- Sponsor
- AstraZeneca
Malignant Neoplasm Other Gallbladder/Extrahepatic Bile Duct
Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma
The present study is designed to determine whether adjuvant concurrent chemoradiotherapy improves overall survivals.
- Trial name
- NCT02798510
- Testing
- Concurrent Chemoradiotherapy, capecitabine, gemcitabine
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Fudan University
Pancreatic Cancer Non-resectable, Bile Duct Cancer
Treatment of Distal Malignant Biliary Obstruction by Uncovered, Partially Covered, or Fully Covered Metal Stents
The goal of this randomized controlled trial is to compare uncovered, partially covered, and fully covered self-expandable metal stents (SEMS) in the palliative treatment of distal malignant biliary obstruction in a Swedish…
- Conditions
- Pancreatic Cancer Non-resectable, Bile Duct Cancer, Papillary Carcinoma, Duodenal Cancer
- Trial name
- NCT06453590
- Testing
- Randomization to uncovered SEMS treating jaundice due to distal malignant biliary obstruction., Randomization to partially covered SEMS treating jaundice due to distal malignant biliary obstruction., Randomization to fully covered SEMS treating jaundice due to distal malignant biliary obstruction.
- Where
- 12 sites in Sweden
- Volunteers
- 450 people
- Sponsor
- Region Stockholm
Perihilar Cholangiocarcinoma
Biliary Drainage Plus HAIC in Locally Advanced pCCA
Biliary drainage and stent placement remains to be the main palliative treatment choice for advanced perihiliar cholangiocarcinoma (pCCA), and the life expectancy is only 4-6 months.
- Trial name
- NCT05024513
- Testing
- oxaliplatin and 5-fluorouracil, Biliary Drainage, Best Supportive Care
- Where
- China
- Volunteers
- 127 people
- Sponsor
- Peking University
Primary Sclerosing Cholangitis (PSC)
Endoscopy and Primary Sclerosing Cholangitis
Primary Sclerosing Cholangitis (PSC) is a chronic, cholestatic, immune-mediated liver disease characterized by segmental inflammation, fibrosis and destruction of the intra and / or extrahepatic biliary tree.
- Trial name
- NCT06686810
- Testing
- Endoscopic Retrogradade CholangioPancreatography (ERCP)
- Where
- Italy
- Volunteers
- 118 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Hepatocellular Carcinoma Stage IIIB, Cholangiocarcinoma, Intrahepatic
Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment
This trial is to evaluate the palliative effects of colchicine on primary hepatic malignancy using the Department of Health R.O.C. approved doses and methods of administration.
- Conditions
- Hepatocellular Carcinoma Stage IIIB, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma; With Hepatocellular Carcinoma, Hepatocellular Carcinoma Stage IV
- Trial name
- NCT04264260
- Testing
- Colchicine Tablets
- Where
- Taiwan
- Volunteers
- 42 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (Icc)
Pragmatic RCT of AI-Assisted Reading for Malignant Hepatic Lesions on CE-CT
The purpose of this multicenter pragmatic randomized controlled trial is to determine whether AI-assisted interpretation of multiphasic liver contrast-enhanced computed tomography (CE-CT) is non-inferior to standard radiology…
- Conditions
- Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (Icc), Hepatic Metastasis, Hepatic Hemangioma
- Trial name
- NCT07768085
- Testing
- AI-assisted abdominal CE-CT reporting, Standard abdominal CE-CT reporting without AI assistance
- Where
- China
- Volunteers
- 40,000 people, healthy volunteers welcome
- Sponsor
- Shengjing Hospital
Cholangiocarcinoma, Bile Duct Inflammation
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture
This study will collect data from patients undergoing an ERCP procedure with probe-based Confocal Laser Endomicroscopy for suspicion of bile duct cancer.
- Trial name
- FOCUS (NCT01392274)
- Where
- 6 sites in United States, France and 1 more
- Volunteers
- 121 people
- Sponsor
- Mauna Kea Technologies
Metastases, Neoplasm, Colorectal Neoplasms
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
MTC-DOX is Doxorubicin or DOX, a chemotherapy drug, that is adsorbed, or made to "stick", to magnetic beads (MTCs). MTCs are tiny, microscopic particles of iron and carbon.
- Conditions
- Metastases, Neoplasm, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms
- Trial name
- NCT00041808
- Testing
- MTC-DOX for Injection, Chemotherapy
- Where
- 4 sites in United States, Germany
- Volunteers
- 20 people
- Sponsor
- FeRx
Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
Collection of Blood and Tissue Samples From Patients With Primary Liver Cancer.
The project aims to collect blood, tissue samples, and clinical data from patients with primary liver cancer (mainly hepatocellular carcinoma and intrahepatic cholangiocarcinoma) undergoing systemic therapy, surgical resection…
- Trial name
- NCT06899854
- Where
- Italy
- Volunteers
- 53 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Cholangiocarcinoma
Coregistration of 18F-FDG-PET and MRI in the Staging of Potentially Resectable Hilar Cholangiocarcinoma: a Pilot Study
To evaluate the feasibility and performance of coregistered 18F-FDG-PET/MRI in the staging of potentially respectable hilar cholangiocarcinoma.
- Trial name
- PET/MRCP (NCT00604266)
- Where
- Canada
- Sponsor
- University of Toronto
Hepatocellular Carcinoma , Cholangiocarcinoma
Clinical Study of Intratumoral Injection of CAR-T Cells in the Treatment of Advanced Liver Tumors
Objective to study the safety and preliminary efficacy of intratumoral injection of CAR-T cells in the treatment of advanced liver tumors.
- Trial name
- NCT04951141
- Testing
- anti-GPC3 CAR-T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Unresectable and Advanced Cholangiocarcinoma
A Study of Sunitinib in Patients With Advanced Cholangiocarcinoma
For patients with non-resectable cholangiocarcinoma, gemcitabine with cisplatin is considered as the reference treatment in first line chemotherapy.
- Trial name
- SUN-CK (NCT01718327)
- Testing
- Sunitinib
- Where
- 6 sites in France
- Volunteers
- 53 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Breast Carcinoma, Cholangiocarcinoma
Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer
This trial studies nutritional preferences and product accessibility in oral nutritional supplements in participants with breast, colorectal, upper gastrointestinal, or prostate cancer.
- Conditions
- Breast Carcinoma, Cholangiocarcinoma, Colorectal Carcinoma, Gastric Carcinoma
- Trial name
- NCT03563352
- Testing
- Interview, Survey Administration
- Where
- United States
- Sponsor
- University of Southern California
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.